TY - JOUR
T1 - Outcome of human umbilical cord blood stem cell transplantation (CBT) for acute myeloid leukemia in patients achieving first complete remission after one versus two induction courses
T2 - a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
AU - Nagler, Arnon
AU - Labopin, Myriam
AU - Cornelissen, Jan J.
AU - Forcade, Edouard
AU - Chevallier, Patrice
AU - Fegueux, Nathalie
AU - Sierra, Jorge
AU - Desmier, Deborah
AU - Labussière-Wallet, Hélène
AU - Byrne, Jenny L.
AU - Loschi, Michael
AU - Blaise, Didier
AU - Baron, Frederic
AU - Ruggeri, Annalisa
AU - Mohty, Mohamad
N1 - Funding Information:
We thank all the EBMT centers and national registries for contributing patients to this study (Supplementary Appendix material ). We also thank the data managers for their excellent work.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/10
Y1 - 2022/10
N2 - We compared transplantation outcomes of adult patients with AML that underwent cord blood transplantation (CBT) in CR1 following 1 versus 2 induction courses. Study included 325 patients, 243 (75%) with 1 and 82 (25%) with 2 induction courses. Engraftment was lower for patients achieving CR1 after 1 vs. 2 induction courses: 91% vs. 99% (p = 0.02). Incidence of acute GVHD was similar, 38% and 36% (p = 0.81), as was 2-year chronic GVHD at 23.4% and 27.5%, respectively (p = 0.65). Two-year non-relapse mortality (NRM), relapse incidence (RI), leukemia-free survival (LFS), overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were not statistically different between patients achieving CR1 with 1 vs. 2 induction courses with 23% vs. 24% (p = 0.87), 25% vs. 30% (p = 0.4), 52% vs. 46% (p = 0.3), 59% vs. 50% (p = 0.2), and 44% vs. 41% (p = 0.66), respectively. Results were confirmed by multivariable analysis, NRM (hazard ratio (HR) = 1.1; 95% CI, 0.6–1.8, p = 0.7), RI (HR = 1.4; 95% CI, 0.9–2.3, p = 0.1), LFS (HR = 1.3; 95% CI, 0.9–1.8, p = 0.2), OS (HR = 1.3; 95% CI, 0.9–1.9, p = 0.1), and GRFS (HR = 1.1; 95% CI, 0.8–1.5, p = 0.5). Overall, outcomes of AML patients undergoing CBT in CR1 achieved after 1 or 2 induction courses are similar.
AB - We compared transplantation outcomes of adult patients with AML that underwent cord blood transplantation (CBT) in CR1 following 1 versus 2 induction courses. Study included 325 patients, 243 (75%) with 1 and 82 (25%) with 2 induction courses. Engraftment was lower for patients achieving CR1 after 1 vs. 2 induction courses: 91% vs. 99% (p = 0.02). Incidence of acute GVHD was similar, 38% and 36% (p = 0.81), as was 2-year chronic GVHD at 23.4% and 27.5%, respectively (p = 0.65). Two-year non-relapse mortality (NRM), relapse incidence (RI), leukemia-free survival (LFS), overall survival (OS) and GVHD-free, relapse-free survival (GRFS) were not statistically different between patients achieving CR1 with 1 vs. 2 induction courses with 23% vs. 24% (p = 0.87), 25% vs. 30% (p = 0.4), 52% vs. 46% (p = 0.3), 59% vs. 50% (p = 0.2), and 44% vs. 41% (p = 0.66), respectively. Results were confirmed by multivariable analysis, NRM (hazard ratio (HR) = 1.1; 95% CI, 0.6–1.8, p = 0.7), RI (HR = 1.4; 95% CI, 0.9–2.3, p = 0.1), LFS (HR = 1.3; 95% CI, 0.9–1.8, p = 0.2), OS (HR = 1.3; 95% CI, 0.9–1.9, p = 0.1), and GRFS (HR = 1.1; 95% CI, 0.8–1.5, p = 0.5). Overall, outcomes of AML patients undergoing CBT in CR1 achieved after 1 or 2 induction courses are similar.
UR - http://www.scopus.com/inward/record.url?scp=85133201726&partnerID=8YFLogxK
U2 - 10.1038/s41409-022-01742-2
DO - 10.1038/s41409-022-01742-2
M3 - Article
C2 - 35773347
AN - SCOPUS:85133201726
SN - 0268-3369
VL - 57
SP - 1514
EP - 1519
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 10
ER -